Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient's tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation.
No takes yet. Share an insight, caveat, or question.
Fritsch et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: